Trending Down-0.5850 (-2.5281%)
  • Bid / Lots
    22.4500/ 2
  • Ask / Lots
    22.6200/ 2
  • Open / Previous Close
    23.1900 / 23.1400
  • Day Range
    Low 22.5000
    High 23.6900
  • 52 Week Range
    Low 5.6326
    High 26.3500
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 23.14
09:32 ET487223.305
09:33 ET89523.6
09:37 ET35023.47
09:39 ET150023.5
09:46 ET21823.47
09:48 ET1017623.505
09:50 ET40023.485
09:51 ET10023.505
09:53 ET170023.65
09:57 ET10023.625
10:09 ET173823.41
10:15 ET22423.5858
10:22 ET270023.5974
10:29 ET60023.54
10:33 ET10023.425
10:38 ET10423.445
10:42 ET10023.445
10:47 ET207923.525
10:51 ET106523.2
11:02 ET240022.91
11:03 ET32723.19
11:12 ET20022.9916
11:14 ET905023
11:21 ET10023.1886
11:23 ET48523.12
11:25 ET16323.061
11:39 ET10023.12
11:45 ET20023.062
11:48 ET124323.19
11:56 ET10023.185
12:12 ET20023.235
12:14 ET10023.175
12:21 ET10023.24
12:30 ET10023.175
12:48 ET10023.165
12:55 ET10023.165
01:06 ET10023.165
01:09 ET475822.89
01:11 ET127722.72
01:27 ET222322.555
01:31 ET10022.555
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNAMS
NewAmsterdam Pharma Company NV
United StatesDNLI
Denali Therapeutics Inc
United StatesVCEL
Vericel Corp
United StatesRCUS
Arcus Biosciences Inc
United StatesARDX
Ardelyx Inc
United StatesALPN
Alpine Immune Sciences Inc
As of 2024-02-26

Company Information

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

Contact Information

Gooimeer 2-35NAARDEN, Netherlands 1411 DC


Independent Chairman of the Board
William Lewis
Chief Executive Officer, Executive Director
Michael Davidson
Vice Chairman of the Board
Juliette Audet
Interim Chief Financial Officer
Louise Kooij
Chief Operating Officer
Douglas Kling

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.